Vertex & CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorization for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia.